Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

NCT02428985 · clinicaltrials.gov ↗

COMPLETED

Status

882

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension, Pulmonary

Interventions

DRUG: Riociguat (ADEMPAS, BAY63-2521)

Sponsor

Bayer